Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis

Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis
100%89%78%May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 20 • YES 100.0%
Savara Inc. ($SVRA)
No stock close$5.36$4.99$4.63May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 11 • SVRA $5.12May 12 • SVRA $5.08May 13 • SVRA $5.27May 14 • SVRA $5.27May 15 • SVRA $5.03May 18 • SVRA $4.91May 19 • SVRA $4.72May 20 • SVRA $4.89
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Resolved Date
5/20/26
Study Completion
5/30/27
Sponsor
Savara Inc.
Ticker
$SVRA
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
164
NCT
NCT04544293
Trial Description
This Phase 3 trial tested inhaled molgramostim in adults with autoimmune pulmonary alveolar proteinosis, measuring lung gas-transfer improvement at 24 weeks.